Challenges and New Developments in the Diagnosis and Treatment of Sarcoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 128
Special Issue Editor
Interests: prognostic and predictive biomarkers; novel therapeutic intervention through genomic and transcriptome sequencing; clinical, translational research, and clinical trials (breast/sarcoma)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Due to its extreme rarity, heterogeneity, and complexity, sarcoma is considered one of the most challenging diseases and cancers to diagnose and treat, and it therefore presents a poor prognosis in most advanced or metastatic settings. We are currently facing many challenges in the diagnosis and treatment of sarcoma. With the availability of next-generation sequencing technology, novel fusions have been identified, facilitating the evolution of WHO classification, but the biology of these new fusions is not yet understood. Despite the fact that molecular targeted treatments and immunotherapy have revolutionized treatment in the majority of hematological and solid cancer types, they have not yet been applied to sarcoma. The purpose of this Special Issue is to provide opportunities for sarcoma research communities to contribute new ideas and options to promote better diagnosis and treatment in this deadly disease. For this Special Issue, we welcome the submission of reviews and original research articles, with a deadline of 31 December 2025.
Dr. Xiaolan Feng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bone and soft tissue sarcoma
- prognostic and predictive biomarker
- transcriptomic/genomic profiling
- immunotherapy
- targeted treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
